-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Antibody drug conjugates(ADC) cancer therapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Antibody drug conjugates(ADC) cancer therapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
Epidermolysis Bullosa – Drugs In Development, 2023
Global Markets Direct’s, ‘Epidermolysis Bullosa - Drugs In Development, 2023’, provides an overview of the Epidermolysis Bullosa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Company Profile
Amryt Pharma Plc – Company Profile
Amryt Pharma Plc (Amryt) is a biopharmaceutical company that develops and commercializes novel treatments for patients with rare and orphan diseases. It has two marketed products including lomitapide for the treatment of adult HoFH and Metreleptin for the treatment of leptin deficiency. The company is also developing a portfolio of pipeline candidates, Oleogel-S10 and AP103 targeting multiple orphan diseases such as epidermolysis bullosa. The company offers its products in the US, Europe, the Middle East and Africa (EMEA). Amryt Pharma...
Add to Basket -
Product Insights
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leptin Receptor (LEPR) Drugs in Development Report Overview Leptin receptor or LEP-R is a protein encoded by the LEPR gene and acts as a receptor for the hormone LEP/leptin. The Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) drugs in development research report provides comprehensive information on the therapeutics under development for LEPR. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication. The pipeline report...
-
Product Insights
Neuroendocrine Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neuroendocrine Tumors Pipeline Drugs Market Report Overview Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. The Neuroendocrine Tumors pipeline drugs market research report provides comprehensive information on the therapeutics under development for...
-
Product Insights
Radiodermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Radiodermatitis is an inflammation of the skin caused by radiation. The Radiodermatitis pipeline market research report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Net Present Value Model: Lojuxta
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Lojuxta Drug Details Lomitapide (Lojuxta/Juxtapid) belongs...
-
Product Insights
Net Present Value Model: Mycapssa
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Mycapssa Drug Details Octreotide acetate (Mycapssa)...
-
Product Insights
Net Present Value Model: Episalvan/Filsuvez/Oleogel-S10
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Episalvan/Filsuvez/Oleogel-S10 Drug Details Birch bark extract...